Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.USFDA accepts NextPoint Therapeutics’s IND for NPX887
With this acceptance, NextPoint Therapeutics now intends to begin a first-in-human Phase I clinical trial in early 2024 analysing NPX887 in patients with solid tumours known to express
With this acceptance, NextPoint Therapeutics now intends to begin a first-in-human Phase I clinical trial in early 2024 analysing NPX887 in patients with solid tumours known to express
ALS is a progressive neurodegenerative disease which sees motor neurons atrophy and die, leading to loss of the ability to speak, move, eat and, ultimately even breathe. Voyager
People suffering with PNH condition have an acquired mutation that makes their red blood cells susceptible to destruction in a premature way by the complement system. A Factor
The new, first-in-class inhibitor is being assessed to treat a range of immune-mediated disorders, including lupus nephritis (LN), the most common secondary immune-mediated glomerular disease. Following the acceptance,
ELAHERE is a first-in-class antibody-drug conjugate (ADC) approved for platinum-resistant ovarian cancer (PROC). The deal will see ImmunoGen’s follow-on pipeline of next-generation ADCs complement the ADC platform and
The partnership has been formed through Astella’s wholly-owned subsidiary Xyphos Biosciences. They will assess the potential of antibodies, developed by Phenomic and designed for a novel tumour stroma
Schizophrenia is a long-lasting mental illness that can significantly affect a person’s thoughts, emotions, and behaviours. It impacts nearly 24 million people globally, with 2.8 million affected in
The partnership will utilise Accutar’s artificial intelligence (AI) platform and Evommune’s expertise to design and develop novel oral small molecule treatments for targets, which are the root cause
The Hemophilia A programme integrates the Sernova Cell Pouch with a patient’s cells, eliminating the need for immunosuppression medications. This treatment aims to substitute Factor VIII (FVIII), a
The company has filed the applications based on Revascor’s data from a randomised, blinded, controlled prospective study carried out at a single centre in the US involving 19